by GlyTherix | Feb 21, 2023
ANSTO to supply Lutetium-177 for GlyTherix’s Phase Ib therapeutic trial in patients with prostate, pancreatic and bladder cancers Phase Ib basket clinical trial expected to start in late 2023 Sydney, Australia – February 21, 2023 – GlyTherix Ltd, an Australian...
by GlyTherix | Dec 20, 2022
December 20, 2022 – GlyTherix Ltd (“GlyTherix”), an Australian immuno-oncology company today announced an MTA & Option License with Adcendo ApS (“Adcendo”), a Danish biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the...
by GlyTherix | Sep 8, 2022
GlyTherix Ltd today announces that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of a consortium of applicants led by The University of Queensland....
by GlyTherix | Jul 21, 2022
Date, July 21 2022: Sydney. GlyTherix is pleased to announce the successful completion of its high-yield GMP-grade stable cell line development program for its proprietary antibody Miltuximab® in partnership with international biologics manufacturer GenScript ProBio...
by GlyTherix | Jul 8, 2022
Date, July 8 2022: Sydney. GlyTherix has commenced an exciting new collaboration with the GastroEsophageal Malignancies Investigator Network Initiative (GEMINI) to test its Miltuximab® monoclonal antibody therapies in gastroesophageal cancers. GEMINI, backed by the...
by GlyTherix | Dec 1, 2021
GlyTherix is pleased to announce the award of a $50,000 COVID-19 TechVoucher by the NSW Government through Investment NSW that will provide funding support to collaborate with ANSTO’s world-leading radiochemistry and preclinical imaging teams. Funds will be used to...
